65 activities found

Expert Perspectives: Irritable Bowel Syndrome with Diarrhea (IBS-D) - Targeting Etiology with Emerging Therapies

In this Expert Perspectives activity, Dr. Nicholas Talley leads a conversation with Drs. Brian Lacy and Baharak Moshiree based on a CME symposium they presented at the Annual American College of Physicians Conference in May 2016 that discussed interpretation of best practices and recent advancements in the management of IBS-D and their application to clinical practice. The expert panel highlight new therapies and their use in combination with other supportive therapies, expound upon the diagnosis of underlying etiology, and provide a review of therapies under investigation.
0.5 CME

Key Insights: 2016 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes

Clinical outcomes and quality of life in patients with MPN and MDS continue to be enhanced as cytogenetic analysis and novel therapeutic strategies are incorporated into disease management regimens. Recently proposed changes to refine and strengthen diagnostic and risk-assessment models, along with the rapid evolution of disease management strategies that utilize standard of care and/or novel therapeutic agents, will likely further enhance clinical outcomes in patients with MPN and MDS and improve their quality of life. This online enduring activity provides a summary of the most intriguing and clinically applicable topics and data, outlines key learning points, and reinforces the take-home messages from the Congress.
0.5 CME

Webcast: MPN Therapies - Emerging Concepts for Enhanced Outcomes

Standard of care treatment for patients with PV or ET requiring cytoreductive therapy is hydroxyurea (HU), but recent reports pertaining to leukemic transformation events and resistance/intolerance have put HU’s continued use as an optimal first-line therapy into question. IFN-a is also ELN-recommended for first- and second-line therapy of patients with PV and ET, and newer formulations are providing patients with significant hematologic and molecular responses with reduced toxicities. As data from studies utilizing novel IFN-a therapeutic regimens mature and significant clinical improvements are further elucidated, it is imperative that European healthcare professionals involved in the care of patients with PV and ET are provided with expert review and analysis of the most pertinent clinical data pertaining to optimal first- and second-line cytoreductive strategies and guidance for their integration into everyday clinical practice for the enhancement of patient outcomes and quality of life.
1 CME

Webcast: Individualizing Late-Line Treatment for Patients with Metastatic Colorectal Cancer

Recent advances in the management of patients with metastatic colorectal cancer (mCRC) who have progressed after failing first- and second-line therapies have dramatically improved survival outcomes in the third- and later-line settings. While the standard of care for these difficult-to-treat patients is improving, many clinicians lack the ability to effectively evaluate and interpret the emerging data of novel therapeutics and to plan effective treatment strategies to apply them in practice. To this end, this webcast highlights the clinically significant information presented during the Individualizing Late-Line Treatment for Patients with Metastatic Colorectal Cancer Symposium in New York, New York, on April 1, 2016.
0.75 CME

Expert Perspectives: Optimizing Late-Line Therapy for Patients with Metastatic Colorectal Cancer

In recent years, there have been tremendous advancements in the management of patients with metastatic colorectal cancer (CRC) who have progressed after failing first- and second-line therapies. Notably, data from pivotal phase III trials have demonstrated dramatically improved survival outcomes in patients with metastatic CRC in the third- and later- line settings. Moreover, there are several other agents currently in early-phase trials that are yielding significant clinical benefits. As the standard of care for these difficult-to-treat patients is improving, many clinicians are challenged to formulate effective management strategies to offer optimal patient-centered care in the clinical setting. To this end, this activity presents a discussion between world-renowned thought leaders who elucidate the effective implementation of new late-line CRC treatments in the clinical setting.
0.75 CME

Key Insights: Great Debates & Updates in Hematologic Malignancies 2016

The continued evolution and refinement of strategies for disease diagnosis, risk assessment, therapeutic intervention and disease management have provided patients with hematologic malignancies and benign hematologic disorders with enhanced outcomes and improved quality of life. The 2016 Great Debates & Updates in Hematologic Malignancies conference, held April 1-2 in New York, NY, provided clinicians with the most current and pertinent data in the areas of multiple myeloma (MM), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), acute leukemia, myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), lymphoma and benign hematology. This Key Insights™ activity provides a summary of the key "take-home" points from the meeting.
0.75 CME

Webcast: Great Debates & Updates in GI Malignancies 2016

There have been tremendous advancements in the multidisciplinary management of GI cancers in the past decade, with a growing number of new and improved targeted agents and efficacious combination regimens yielding substantial clinical benefits in both early and late stages of the diseases. Moreover, breakthroughs in molecular profiling, cancer immunology, early stage detection, and novel diagnostic techniques have led to accelerated strides in GI cancer research and management. As the field of GI malignancies is continuously evolving, community oncologists must strive to keep abreast of the latest developments and resolve new issues in optimizing the management of esophageal, gastric, hepatocellular, pancreatic, and colorectal cancers. To this end, this webcast highlights the clinically significant information presented during the 2016 Great Debates and Updates in GI Malignancies in New York, New York from April 1-2, 2016.
8 CME

Key Insights: Great Debates & Updates in Inflammatory Bowel Disease 2016 - Adult Session

This Key Insights activity serves to provide a brief synopsis of the key points presented on inflammatory bowel diseases at the Great Debates and Updates in Inflammatory Bowel Disease conference held in San Francisco, California from March 18-19, 2016. Dr. Marla Dubinsky’s expert review moderated by Dr. Joel Rosh covers recent developments in counseling of pregnant patients, psychosocial care, health maintenance, treat to target. management of post-operative IBD, and malignancy.
0.5 CME

Key Insights: Great Debates & Updates in Inflammatory Bowel Disease 2016 - Pediatric Session

This Key Insights activity serves to provide a brief synopsis of the key points presented on pediatric inflammatory bowel diseases at the Great Debates and Updates in Inflammatory Bowel Disease held in San Francisco, California from March 18-19, 2016. Dr. Joel Rosh’s expert review moderated by Dr. Marla Dubinsky covers recent developments in diagnosis, phenotyping and risk stratification, epidemiology, environment and pathogenesis of IBD, mucosal healing as a treatment target, optimization of therapy and perianal Crohn’s disease and pouch complications.
0.5 CME

Key Insights: 13th Annual Best of San Antonio - Breast Cancer: Bench to Bedside

Advancements in breast cancer care continue to rapidly evolve and the San Antonio Breast Cancer Symposium (SABCS) is the premier annual forum for exchange of new scientific and clinical information. However, not all healthcare professionals have the opportunity to attend this meeting and even those that do attend often can benefit from taking a deeper dive into the relevance of the data in a smaller venue in which more intimate faculty and peer interactions can take place. This is the role of the annual Best of San Antonio - Breast Cancer: Bench to Bedside meeting—to help practicing clinicians interpret the most clinically-relevant data presented during the SABCS and apply it in their practice of caring for patients with breast cancer. This webcast features Chair, Kathy Albain, MD, FACP, FASCO discussing highlights from the 13th Annual Best of San Antonio - Breast Cancer: Bench to Bedside.
1 CME